This site is intended for healthcare professionals
News

SOPHIA Phase III study of Margenza announces final OS data in HER2-positive breast cancer patients.

Read time: 1 mins
Last updated:9th Sep 2021
Published:9th Sep 2021
MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase III study of Margenza (margetuximab-cmkb) in adult patients with metastatic HER2-positive breast cancer.
Condition: Breast Cancer HER2+
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest